Astria Therapeutics, Inc. Stock News

As the year wound to a close, biotechs were in focus among the notable insider purchases.

Astria Therapeutics, Inc. (NASDAQ:ATXS ) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Elizabeth Higgins - Investor Relations Jill Milne - Co Founder, CEO, Preside

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced tha

Astria Therapeutics has inked a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio targeting the potential treatment of atopic dermatitis (AD) and other allergic and immu

Astria Therapeutics (formerly Catabasis Pharma) has raised $100 million and acquired Quellis to develop STAR-0215, a plasma kallikrein inhibitor for hereditary angioedema (HAE). STAR-0215 has a longer

Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to treat hereditary angioedema. The stock rises 5%.

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapi

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for

Astria: Biotech To Watch With Proof Of Concept Established For HAE.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Astria Therapeutics, Inc. (ATXS) could be a great choice. It is one of the several stocks that passed through o

ATXS has broken out from a 37-week price reversal. Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of swelling in various parts of the body.

The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that the Company wi

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that it will share

Astria Therapeutics, Inc. (ATXS) CEO Jill Milne on Q3 2021 Results - Earnings Call Transcript